Related Experiment Video
Updated: Jul 3, 2025

Antimicrobial Peptides Produced by Selective Pressure Incorporation of Non-canonical Amino Acids
Published on: May 4, 2018
An enhanced broad-spectrum peptide inhibits Omicron variants in vivo
Wenwen Bi1, Kaiming Tang2, Guilin Chen3
1Research Center for Industries of the Future and Key Laboratory of Structural Biology of Zhejiang Province, School of Life Sciences, Westlake University, Hangzhou 310030, Zhejiang, China; Frontier Biotechnology Laboratory, ZJU-Hangzhou Global Scientific and Technological Innovation Center, Zhejiang University, Hangzhou 311215, China; Center for Infectious Disease Research, Westlake Laboratory of Life Sciences and Biomedicine, Hangzhou 310030, Zhejiang, China; Institute of Biology, Westlake Institute for Advanced Study, Hangzhou 310030, China.
Abstract:
The continual emergence of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) variants of concern (VOCs) poses a major challenge to vaccines and antiviral therapeutics due to their extensive evasion of immunity. Aiming to develop potent and broad-spectrum anticoronavirus inhibitors, we generated A1-(GGGGS)7-HR2m (A1L35HR2m) by introducing an angiotensin-converting enzyme 2 (ACE2)-derived peptide A1 to the N terminus of the viral HR2-derived peptide HR2m through a long flexible linker, which showed significantly improved antiviral activity. Further cholesterol (Chol) modification at the C terminus of A1L35HR2m greatly enhanced the inhibitory activities against SARS-CoV-2, SARS-CoV-2 VOCs, SARS-CoV, and Middle East respiratory syndrome coronavirus (MERS-CoV) pseudoviruses, with IC50 values ranging from 0.16 to 5.53 nM. A1L35HR2m-Chol also potently inhibits spike-protein-mediated cell-cell fusion and the replication of authentic Omicron BA.2.12.1, BA.5, and EG.5.1. Importantly, A1L35HR2m-Chol distributed widely in respiratory tract tissue and had a long half-life (>10 h) in vivo. Intranasal administration of A1L35HR2m-Chol to K18-hACE2 transgenic mice potently inhibited Omicron BA.5 and EG.5.1 infection both prophylactically and therapeutically.
Insights
A novel cholesterol-modified peptide, A1L35HR2m-Chol, demonstrates potent broad-spectrum antiviral activity against SARS-CoV-2 variants and other coronaviruses. This inhibitor shows promise for respiratory tract infections with effective in vivo prophylactic and therapeutic effects.
Area of Science:
- Virology
- Drug Discovery
- Biochemistry
Background:
- Emergence of SARS-CoV-2 variants of concern (VOCs) challenges existing vaccines and therapeutics.
- Viral immune evasion necessitates development of broad-spectrum antiviral inhibitors.
Purpose of the Study:
- To develop potent and broad-spectrum inhibitors against coronaviruses, including SARS-CoV-2 VOCs.
- To evaluate the efficacy of a novel peptide inhibitor, A1L35HR2m-Chol, against SARS-CoV-2 and other coronaviruses.
Main Methods:
- Generation of A1L35HR2m by linking an ACE2-derived peptide to a viral HR2-derived peptide via a flexible linker.
- Cholesterol modification of A1L35HR2m to create A1L35HR2m-Chol.
- In vitro assays using pseudoviruses and authentic SARS-CoV-2 variants (Omicron BA.2.12.1, BA.5, EG.5.1).
- In vivo studies involving intranasal administration to K18-hACE2 transgenic mice.
Main Results:
- A1L35HR2m-Chol exhibited enhanced inhibitory activity against SARS-CoV-2, VOCs, SARS-CoV, and MERS-CoV pseudoviruses (IC50: 0.16–5.53 nM).
- The inhibitor effectively blocked spike-protein-mediated cell-cell fusion and replication of authentic Omicron variants.
- A1L35HR2m-Chol showed wide distribution in respiratory tissues and a long in vivo half-life (>10 h).
- Intranasal A1L35HR2m-Chol provided potent prophylactic and therapeutic protection against Omicron BA.5 and EG.5.1 infection in mice.
Conclusions:
- A1L35HR2m-Chol is a potent broad-spectrum antiviral agent against SARS-CoV-2 and other coronaviruses.
- The inhibitor demonstrates favorable pharmacokinetic properties and significant therapeutic potential for respiratory coronavirus infections.
More Related Videos
08:31Biosensor-based High Throughput Biopanning and Bioinformatics Analysis Strategy for the Global Validation of Drug-protein Interactions
Published on: December 1, 2020
08:48Development of a Backbone Cyclic Peptide Library as Potential Antiparasitic Therapeutics Using Microwave Irradiation
Published on: January 26, 2016
Related Concept Videos
Antimicrobial Proteins
Interferons
Interferons (IFNs) are proteins produced by lymphocytes, macrophages, and fibroblasts infected with viruses. While IFNs cannot prevent viruses from entering and...
Leaky Scanning